- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00447187
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was intended for surgical episcleral placement in the eye.
The study was a Phase 2/3, multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study of LX201 for prevention of corneal allograft rejection or graft failure following penetrating keratoplasty with LX201 implantation. Subjects were to be followed in an outpatient setting for safety and efficacy at 4-6 week intervals for 52 weeks following transplantation surgery.
After Visit 12 (Week 52), subjects in the USA and India with the implant in the study eye were to be followed for safety at least once per year for a 2-year period or until time of implant removal. For subjects in the USA and India, if the implant was removed at any time prior to the 3 year safety follow-up, the subject was to have a final safety follow up visit at 3 months post removal. In Germany, the implant was to be removed at Week 52 with a 3-month safety follow-up period after removal.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85032
- Cornea Consultants of Arizona
-
-
California
-
Loma Linda, California, Förenta staterna, 92354
- Loma Linda University Health Care
-
Los Angeles, California, Förenta staterna, 90033
- USC Doheny Eye Institute
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- Bascom Palmer Eye Institute
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Emory Eye Center
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- University Of Illinois at Chicago
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46260
- Price Vision Group
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21218
- The Eye Center at Union Memorial Hospital
-
Baltimore, Maryland, Förenta staterna, 21287
- Wilmer Eye Institute, Cornea Service
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02111
- New England Eye Center
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48105
- W.K. Kellogg Eye Center - University of Michigan
-
-
Minnesota
-
Bloomington, Minnesota, Förenta staterna, 55431
- MN Eye Consultants, P.A.
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64111
- Tauber Eye Center
-
St. Louis, Missouri, Förenta staterna, 63141
- Ophthalmology Associates
-
-
New Jersey
-
Newark, New Jersey, Förenta staterna, 07103
- UMDNJ - New Jersey Medical School Institute of Ophthalmology and Visual Science
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Mount Sinai School of Medicine
-
New York, New York, Förenta staterna, 10003
- New York Eye and Ear Infirmary
-
Rockville Center, New York, Förenta staterna, 11570
- Ophthalmic Consultants of Long Island
-
Slingerlands, New York, Förenta staterna, 12159
- Cornea Consultants of Albany
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Duke University Eye Center
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- University Hospitals Case Medical Center
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75231
- Cornea Associates of Texas
-
-
Virginia
-
Norfolk, Virginia, Förenta staterna, 23502
- Virginia Eye Consultants
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98104
- Eye Associates NW
-
-
-
-
-
Erlangen, Tyskland, 91054
- Augenklinik, Universitat Erlangen-Nurnberg
-
Essen, Tyskland, 45122
- Cornea Bank, Universitätsklinikum Essen
-
Kiel, Tyskland, 24105
- Klinik fuer Ophthalmologie Campus Kiel
-
Muenchen, Tyskland, 80336
- Ludwig Maximilians Universität
-
München, Tyskland, 81675
- Augenklinik der Technischen Universität München
-
Wuerzburg, Tyskland, 97080
- Augenklinik Wuerzburg
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Subjects are candidates for a corneal transplant and are at increased immunological risk for graft failure, as evidenced by one or more of the following:
- ≥ 1 quadrant deep corneal vascularization
- verifiable history of graft failure due to rejection
- position of graft is < 1 mm from the limbus
Exclusion Criteria:
- Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis.
- Schirmer's test ≤ 5 mm in 1 minute
- Clinical evidence of limbal stem cell deficiency
- History of or active herpes simplex virus keratitis or other acute corneal infection
- Subjects who have had > 3 failed grafts in the study eye
- Uncontrolled glaucoma as evidenced by an intraocular pressure of >21 mmHg while on maximal medical therapy
- Clinically suspected or confirmed ocular lymphoma
- Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted.
- Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ TA intravitreal implant)
- Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease).
- Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months
- History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment
- Seropositivity for human immunodeficiency virus (HIV)
- Previous exposure or known contraindication to administration of cyclosporine
- Recipients of a solid organ transplant
- Currently pregnant or lactating
- Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C
- Severe anemia (hemoglobin < 6 g/dL), leukopenia (white blood cell count [WBC] < 2500 mm3), thrombocytopenia (platelet count < 80,000 mm3), polycythemia (hematocrit [Hct] > 54% [male] or Hct > 49% [female]) or clinically significant coagulopathy
- Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully
- Active peptic ulcer disease
- Co-morbid conditions that require immunosuppression
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: LX201 0,50 tums implantat
LX201-implantatet innehöll 30 viktprocent cyklosporin A och var 0,50 tum långt
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Experimentell: LX201 0,75 tums implantat
LX201-implantatet innehöll 30 % cyklosporin A i vikt och 0,75 tum i längd
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Placebo-jämförare: Placebo 0,75 tums implantat
Silikonimplantat som inte innehåller ciklosporin A, 0,75 tum långt
|
Placebo var ett silikonimplantat med en längd på 0,75 tum.
Den innehöll inget cyklosporin A
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
graft rejection or graft failure
Tidsram: 52 weeks
|
52 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Eddy Anglade, MD, Chief Medical Officer, Lux Biosciences, Inc.
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LX201-01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kornea sjukdomar
-
Haag-Streit AGUniversity Hospital Inselspital, BerneAvslutadCorneal topografiSchweiz
-
Trefoil Therapeutics, Inc.Avslutad
-
Cairo UniversityAvslutad
-
Medipol UniversityAvslutad
-
Umeå UniversityGlaukos CorporationAvslutadÖgonsjukdomar | Keratokonus | Hornhinnas sjukdom | Korneal tvärbindning | Corneal biomekanik | Corneal densitometri | Scheimpflug fotografiSverige
-
Tianjin Eye HospitalAvslutadCorneal biomekanik | Ciliarmuskeltjocklek | Anterior Sclera Tjocklek | CASIA2Kina
-
Sohag UniversityHar inte rekryterat ännu
-
University Hospitals Cleveland Medical CenterAlcon ResearchAvslutadMyopi | Hyperopi | Corneal infiltrativa händelserFörenta staterna
-
Cairo UniversityIndragenDiabetes mellitus | Corneal endotelcellsförlust | Dexametason biverkning | Corneal endotelial dekompensation
-
L.V. Prasad Eye InstituteHar inte rekryterat ännu
Kliniska prövningar på LX201
-
Lux Biosciences, Inc.AvslutadKorneatransplantation | Avstötning av hornhinnetransplantatFörenta staterna, Tyskland